Novartis announced that patients with Myelofibrosis initially randomized to treatment with Jakavi (ruxolitinib) lived longer than those randomized to treatment...
Background and objectives: Advocates for dementia-friendly communities emphasize the need for the public to know about the dementias and to experience social comfort with people having dementia.
We propose an integrated and adaptable approach to improve patient care and clinical outcomes through analgesia and light sedation, initiated early during an episode of critical illness and as a priority of care.
Results from a Phase III three-year follow-up study that showed Jakafi/Jakavi (ruxolitinib), from Novartis, demonstrated improved overall survival and sustained...
Can-Fite BioPharma announced that Dr. Kim A. Papp, MD, PhD, presented new data from the Company’s recently completed Phase III COMFORT study at the late-breaking news session of the 31st European Academy of Dermatology and Venerology (EADV) Congress
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) and...